Explore our news bulletins and archive
for the latest press coverage, as well as articles of interest.

Steve Shadowen Announced as American Antitrust Institute 2013 Antitrust Enforcement Awards Finalist
  • November 18, 2013
  • Event

The American Antitrust Institute has announced its selection of leading legal practitioners and economists to be recognized at the AAI 2013 Antitrust Enforcement Awards. Steve Shadowen of Hilliard & Shadowen has been selected as an Outstanding Antitrust Litigation Achievement in Private Law Practice Finalist.

Suits Target Endo, Actavis Over Lidoderm Pay-For-Delay

Law360 reports on recent Lidoderm patch case filed by Hilliard & Shadowen:

Endo Pharmaceuticals Inc. andActavis Inc. have been hit with two putative class actions in the past week in Pennsylvania and California federal courts over their patent settlement that allegedly delayed generic competition for Endo's pain relief patch Lidoderm. Puerto Rican pharmaceutical wholesaler Drogueria Betances launched its antitrust class action Friday in Pennsylvania, and a union health and welfare fund filed a similar complaint Tuesday in California, both alleging that Endo, Actavis and their subsidiaries unlawfully restricted Lidoderm competition with their so-called pay-for-delay deal. That agreement harmed consumers and caused them to pay higher prices for the pain patches, the complaints claimed.

Nexium Buyers Win Class Cert In AstraZeneca Antitrust MDL

Law360 reports on Hilliard & Shadowen's victory in class certification battle in Nexium case:

Massachusetts federal judge certified a class of Nexium end-buyers on Thursday who accused AstraZeneca PLC and others of violating antitrust laws by delaying a generic version of AstraZeneca’s heartburn drug, ruling the class met adequacy and predominance requirements. In the multidistrict litigation, the judge certified a damages class consisting of an unidentified number of individual consumers, third-party payors, union plan sponsors and insurance companies that bought or provided reimbursements for Nexium in more than 20 states and the District of Columbia. The class period will last from Apr. 14, 2008, until the alleged anticompetitve effects of the companies' unlawful conduct end, the judge said. The Nexium buyers allege that AstraZeneca established market power and used that power to harm competition when it entered into agreements with generic-drug makers Ranbaxy Inc., Teva Pharmaceutical Industries Ltd. and Dr. Reddy’s Laboratories Ltd.